Bukowska-Olech Ewelina, Sowińska-Seidler Anna, Szczałuba Krzysztof, Jamsheer Aleksander
Department of Medical Genetics, Poznan University of Medical Sciences, Poznan, Poland.
Department of Medical Genetics, Medical University of Warsaw, Warsaw, Poland.
Birth Defects Res. 2020 May 15;112(9):652-659. doi: 10.1002/bdr2.1676. Epub 2020 Apr 14.
The LRP4 gene encodes the highly conserved low-density lipoprotein receptor-related protein 4 (LRP4), which acts as a co-receptor for sclerostin. Sclerostin and LRP4 negatively regulate WNT/β-catenin signaling pathway and lack of their inhibitory activity leads to constant osteoblastic differentiation. Consequently, increased bone formation occurs, which in the case of LRP4 mutations results in sclerosteosis type 2 (SOST2). Alterations within the LRP4 may also cause Cenani-Lenz syndactyly syndrome (CLSS), congenital myasthenia or isolated syndactyly. Here, we have reported a patient, in whom we found a novel homozygous splice-site variant c.1048+6T>C in LRP4 using whole exome sequencing. The patient was initially misdiagnosed with isolated CLSS-like or Malik-Percin-like syndactyly. However, we have finally refined the diagnosis after comprehensive radiological examination and molecularly confirmed SOST2. Additionally, we have pointed here to the splicing variants as important causative alterations that may be overlooked in the molecular analysis due to the lack of advanced, reliable algorithms, built-into the standard diagnostic pipelines. Using advanced in silico prediction tools of splice-site alterations, including Alamut Visual software, we have demonstrated that the c.1048+6T>C LRP4 variant affects the native donor site and impairs an SC35 enhancer activity. Based on our experience, we recommend comprehensive radiological imaging, including X-ray of the skull in each case of isolated syndactyly resulting from pathogenic variants of LRP4. We suggest that all previously reported patients carrying biallelic LRP4 mutations, who were diagnosed with isolated syndactyly, could actually present with SOST2 that had been unrecognized due to the incomplete clinical and radiological assessment.
LRP4基因编码高度保守的低密度脂蛋白受体相关蛋白4(LRP4),它作为硬化蛋白的共受体发挥作用。硬化蛋白和LRP4对WNT/β-连环蛋白信号通路起负调控作用,缺乏它们的抑制活性会导致成骨细胞持续分化。因此,会出现骨形成增加的情况,在LRP4发生突变时会导致2型骨硬化症(SOST2)。LRP4内的改变也可能导致塞纳尼-伦茨并指综合征(CLSS)、先天性肌无力或单纯并指。在此,我们报告了一名患者,通过全外显子组测序在该患者的LRP4基因中发现了一种新的纯合剪接位点变异c.1048+6T>C。该患者最初被误诊为单纯的CLSS样或马利克-佩尔辛样并指。然而,经过全面的放射学检查后,我们最终明确了诊断,并通过分子检测确诊为SOST2。此外,我们在此指出,由于标准诊断流程中缺乏先进、可靠的算法,剪接变异可能是重要的致病改变,在分子分析中可能会被忽视。使用包括Alamut Visual软件在内的先进的剪接位点改变的计算机预测工具,我们证明了c.1048+6T>C的LRP4变异影响天然供体位点并损害SC35增强子活性。根据我们的经验,我们建议对每例由LRP4致病变异导致的单纯并指患者进行全面的放射学成像检查,包括颅骨X线检查。我们认为,所有先前报道的携带双等位基因LRP4突变且被诊断为单纯并指的患者,实际上可能患有因临床和放射学评估不完整而未被识别的SOST2。